(Q33758413)

English

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) (English)

1 reference

Europe PubMed Central

29 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Martin S. Tallman

4

object named as

Martin S Tallman

1 reference

Europe PubMed Central

29 July 2017

Elisabeth Paietta

11

object named as

Elisabeth Paietta

1 reference

Europe PubMed Central

29 July 2017

Ranjana H. Advani

object named as

Ranjana Advani

3

1 reference

ORCID Public Data File 2021

Branimir Ivan Sikic

5

object named as

Branimir I Sikic

1 reference

Europe PubMed Central

29 July 2017

author name string

Peter L Greenberg

1

1 reference

Europe PubMed Central

29 July 2017

Sandra J Lee

2

1 reference

Europe PubMed Central

29 July 2017

Louis Letendre

6

1 reference

Europe PubMed Central

29 July 2017

Kathleen Dugan

7

1 reference

Europe PubMed Central

29 July 2017

Bert Lum

8

1 reference

Europe PubMed Central

29 July 2017

David L Chin

9

1 reference

Europe PubMed Central

29 July 2017

Gordon Dewald

10

1 reference

Europe PubMed Central

29 July 2017

John M Bennett

12

1 reference

Europe PubMed Central

29 July 2017

Jacob M Rowe

13

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

29 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

29 July 2017

22

1 reference

Europe PubMed Central

29 July 2017

1078-1086

1 reference

Europe PubMed Central

29 July 2017

6

1 reference

Europe PubMed Central

29 July 2017

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Pharmacologic approaches to reversing multidrug resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Non-P-glycoprotein drug export mechanisms of multidrug resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Classical multidrug resistance in acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Pharmacological considerations in the modulation of multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Multidrug resistance: clinical relevance in acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Population pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

21 June 2018

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Population pharmacokinetics of etoposide: application to therapeutic drug monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Clinical significance of P-glycoprotein in multidrug resistance malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5457168

30 October 2018

Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Daunorubicin in patients with relapsed and refractory acute nonlymphoblastic leukemia previously treated with anthracycline

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assay for etoposide in human serum using solid-phase extraction and high-performance liquid chromatography with fluorescence detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A sensitive and simple high-performance liquid chromatographic method for the determination of mitoxantrone in plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel assay method for mitoxantrone in plasma, and its application in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/15020609

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2004.07.048

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33758413&oldid=1974563477"